Firm Increasing Capacity to Prepare for Approval for its COVID-19 Saliva Test

Firm Increasing Capacity to Prepare for Approval for its COVID-19 Saliva Test

Firm Increasing Capacity to Prepare for Approval for its COVID-19 Saliva Test By: Tomas Ronolski - AllPennyStocks.com News

Monday, October 4, 2021

As the pandemic continues, shortages of rapid tests are expected. This firm is ramping up production on its less invasive way to test for Covid-19 that is currently waiting on regulatory approval.

Progressive medical device technology company Therma Bright Inc. (TSX Venture: THRM), in anticipation of EUA approval to market its AcuVid Covid-19 Rapid Antigen Saliva Test, has ordered sufficient materials and components to manufacture the first batch of AcuVid tests in the US. 

The firm is also securing multiple manufacturing sites in different countries to be able to meet the anticipated demand for our test in the US and elsewhere.

In a generally dismal day for markets, shares were trading down 1.27% in early-afternoon trade.


Copyright © 2021 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Manufacturing and Wholesale Sales Point to Weakening Economy and Raise Possibilities of Rate Cuts
Drill Less, Extract More: This Just Announced Merger Unlocks Profits
100,000,000 Euro Commitment Sends Shares of this MicroCap Hydrogen Automaker Soaring
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top